RSS

MARS (Minocycline Against Rosacea Study)

International contract development and manufacturing organisation (CDMO), Hovione has announced the enrolment of the first patient in the Phase II clinical trial of its topical minocycline (HY01) in moderate to severe papulopustular rosacea patients. more

News